The treatment of tuberculosis: Current status and future prospects

Expert Opinion on Investigational Drugs

Volumn 7, Issue 4, 1998, Pages 545-552

  Snell, Njc ^a  

^a Bayer Pharma   (United Kingdom)

Author keywords

chemotherapy; immunotherapy; mycobacterial infection; tuberculosis; vaccination

Indexed keywords

EID: 84991420019     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.7.4.545     Document Type: Review

References (43)

1. GRANGE J: Vaccination against tuberculosis: past prob-lems and future hopes. Semin. Respir. Crit. Care Med. (1997) 18: 459 – 470.
2. HOLME C: Trial by TB: a study into current attempts to control the international upsurge in tuberculosis. Proc. Roy Coll. Phys. Edin. (1997) 27 \(Suppl. 4.): 1 – 53.
3. COLSTON J: The return of the great white plague. Biolo-gist (1997) 44: 392 – 394.
4. BAYER R, WILKINSON D: Directly observed therapy for tuberculosis: history of an idea. Lancet (1995) 345: 1545 – 1548.
5. SNELL N, DAVIES P: New treatments for tuberculosis -whose responsibility? Int. J. Tuberc. Lung Dis. (1997) 1 (Suppl. 1): S50.
6. AMERICAN THORACIC SOCIETY OFFICIAL STATEMENT: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. J. Respir. Crit. Care Med. (1994) 149: 1359 – 1374.
7. HOUSTON S, FANNING A: Current and potential treat-ment of tuberculosis. Drugs (1994) 48: 689 – 708.
8. DOOLEY D, CARPENTER J, RADEMACHER S: Adjunctive corticosteroid therapy for tuberculosis: a critical reap-praisal of the literature. Clin. Infect. Dis. (1997) 25: 872 – 887.
9. CALLEJA C, PASCUSSI J, MANI J, MAUREL P, VALAREM M:The antibiotic rifampicin is a nonsteroid ligand and ac-tivator of the human glucocorticoid receptor. Nature Med. (1998) 4: 92 – 96.
10. DROBNIEWSKI F, POZNIAK A, UTTLEY A: Tuberculosis and AIDS. J. Med. Microbiol. (1995) 43: 85 – 91.
11. NAKATA K et al: Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. (1997) 155: 996 – 1003.
12. WHALEN C et al: A trial of three regimens to prevent tu-berculosis in Ugandan adults infected with the human immunodeficiency virus. New EngI J. Med. (1997) 337: 801 – 808.
13. OLLIARO P et al.: Rifabutin for prevention and treat-ment of mycobacterial disease: a review of microbiol-ogy, clinical pharmacology, efficacy and tolerability data. Eur. Respir. Rev. (1995) 5 (25): 77 – 83.
14. UNGHERI D, DELLA BRUNA C, SANFILIPPO A: Studies on the mechanism of action of the spiropiperydil-rifamycin LM427 on rifampicin-resistant M. tubercu-losis. Drugs Exp. Clin. Res. (1984) 10: 681 – 689.
15. KANYOK T: A lesson to be learned. Int. J. Tuberc. Lung Dis. (1997) 1: 490 – 492.
16. BAKER W, MITSCHER L, ARAIN T, SHAWAR R, STOVER C:Recent advances in the chemistry and biology of an-timycobacterial agents. Ann. Rep. Med. Chem. (1996) 31: 161 – 170.
17. YEW W et al.: In vitro activity of quinolones and mac-rolides against mycobacteria. J. Antimicrob. Chemother. (1994) 34: 343 – 351.
18. BERNING S, MADSEN L, ISEMAN M, PELOQUIN C: Long-term safety of ofloxacin and ciprofloxacin in the treat-ment of mycobacterial infections. Am. J. Respk. Crit. Care Med. (1995) 151: 2006 – 2009.
19. KENNEDY N et al.: Randomised controlled trial of adrug regimen that includes ciprofloxacin for the treat-ment of pulmonary tuberculosis. Clin. Infect. Dis. (1996) 22: 827 – 833.
20. HONG KONG CHEST SERVICE /BRITISH MEDICAL RE-SEARCH COUNCIL A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin, and rifampicin. Tuberc. Lung Dis. (1992) 73: 59 – 67.
21. SULLIVAN E et al.: Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet (1995) 345: 1148 – 1150.
22. BANERJEE S, BHATT K, RANA S, MISRA P, CHAKRABORTIP: Involvement of an efflux system in mediating high levels of fluoroquinolone resistance in Mycobacte-rium smegmatis. Biochem. Biophys. Res. Comm. (1996) 226: 362 – 368.
23. LUNA-HERRERA J, REDDY V, GANGADHARAM P: Syner-gistic effect of clarithromycin and isoniazid and ri-fampin against tubercle bacilli. In: Programs and Abstracts of the 34th ICAAC. Orlando, Florida, USA October 1994. American Society for Microbiology (1994). Abstract E 134.
24. WONG C, PALMER G, GYNAMON M: In vitro susceptibil-ity of M tuberculosis, M bovis, and M kansasii to amoxycillin and ticarcillin in combination with clavu-lanic acid. J Antimicrob. Chemother. (1988) 22: 863 – 866.
25. NADLER J, BERGER J, NORD J, COFSKY R, SAXENA M: Amoxicillin - clavulanic acid for treating drug-resistant M tuberculosis. Chest (1991) 99: 1025 – 1026.
26. WAYNE L, SRMEK H: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimi-crob. Agents Chemother. (1994) 38: 2054 – 2058.
27. ASHTEKAR D et al.: In vitro and in vivo activities of the nitroimidazole CGI 17341 against M tuberculosis. Anti-microb. Agents Chemother. (1993) 37: 183 – 186.
28. MEINDL W, VON ANGERER E, SCHONENBERGER H, RUCKDESCHAL G: Benzylamines: synthesis and evalua-tion of antimycobacterial properties. J. Med. Chem. (1984) 27: 1111 – 1118.
29. GRANGE J, SNELL N: Activity of bromhexine and am-broxol, semi-synthetic derivatives of vasicine from the Indian shrub Adhatoda Vasica, against M. tuberculo-sis in vitro. J. Ethnopharmacol (1996) 50: 49 – 53.
30. BARBACHYN M et al.: Identification of a novel oxa-zolidinone (u-100480) with potent antimycobacterial activity. J. Med. Chem. (1996) 39: 680 – 685.
31. ASHTEKAR D et al.: Oxazolidinones, a new class of syn-thetic antituberculosis agents. Diagn. Microbiol. Infect. Dis. (1991) 14: 465 – 471.
32. OPRAVIL M et al.: Dapsone/pyrimethamine may pre-vent mycobacterial disease in immunosuppressed pa-tients infected with the human immunodeficiency virus. Clin. Infect. Dis. (1995) 20: 244 – 249.
33. KANYOK T et al.: In vivo activity of paromomycin against susceptible and multidrug resistant M tuber-culosis and M. avium. Antimicrob. Agents Chemother. (1994) 38: 170 – 173.
34. GANGADHARAM P: Gangamicin, a potential antimyco-bacterial drug. In: Programs and Abstracts of the 3311 ICAAC. New Orleans. Washington, USA American Society for Microbiology (1993). Abstract 73.
35. JAGANNATH C, ALLAUDEEN H, HUNTER R: Activities of polaxamer CRL 8131 against M. tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. (1995) 39: 1162 – 1165.
36. HERZOG H: History of tuberculosis. Respiration (1998) 65: 5 – 15.
37. OTTENHAFF T, SPIERINGS E, NIBBERING P, DE JONG R: Modulation of protective and pathological immunity in mycobacterial infections. Int. Arch. Allergy Immunol (1997) 113: 400 – 408.
38. ROOK G: Intractable mycobacterial infections associ-ated with genetic defects in the receptor for interferon-gamma: what does this tell us about immu-nity to mycobacteria? Thorax (1997) 52 \(Suppl. 3): S41–S46.
39. CONDOS R, ROM W, SCHLUGER N: Treatment of multi-drug resistant pulmonary tuberculosis with inter-feron-y via aerosol. Lancet (1997) 349: 1513 – 1515.
40. GRANGE J: Immunotherapy: a new strategy for tuber-culosis control? Respir. Med. (1997) 91: 1 – 4.
41. ORME I: Progress in the development of new vaccines against tuberculosis. Int. J. Tuberc. Lung Dis. (1997) 1: 95 – 100
42. BARRY C: New horizons in the treatment of tuberculo-sis. Biochem. Pharmacol (1997) 54: 1165 – 1172.
43. ROM W, YIE T-A, TCHOU-WONG K-M: Development of a suicide gene as a novel approach to killing M. tubercu-losis. Am. J. Respir. Crit. Care Med. (1997) 156: 1993 – 1998.